- About this Journal ·
- Abstracting and Indexing ·
- Aims and Scope ·
- Article Processing Charges ·
- Articles in Press ·
- Author Guidelines ·
- Bibliographic Information ·
- Citations to this Journal ·
- Contact Information ·
- Editorial Board ·
- Editorial Workflow ·
- Free eTOC Alerts ·
- Publication Ethics ·
- Reviewers Acknowledgment ·
- Submit a Manuscript ·
- Subscription Information ·
- Table of Contents
Journal of Tropical Medicine
Volume 2013 (2013), Article ID 162950, 6 pages
Anemia among HIV-Infected Patients Initiating Antiretroviral Therapy in South Africa: Improvement in Hemoglobin regardless of Degree of Immunosuppression and the Initiating ART Regimen
1Clinical HIV Research Unit, Department of Internal Medicine, School of Clinical Medicine, Faculty of Health Sciences, University of the Witwatersrand, Johannesburg 2041, South Africa
2Health Economics and Epidemiology Research Office, Department of Internal Medicine, School of Clinical Medicine, Faculty of Health Sciences, University of the Witwatersrand, Johannesburg 2193, South Africa
3Center for Global Health and Development, Boston University, Boston, MA 02118, USA
4Department of Epidemiology, Boston University School of Public Health, Boston, MA 02118, USA
Received 22 April 2013; Revised 14 July 2013; Accepted 14 July 2013
Academic Editor: Marcel Tanner
Copyright © 2013 Simbarashe Takuva et al. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.
- P. S. Sullivan, D. L. Hanson, S. Y. Chu, J. L. Jones, and J. W. Ward, “Epidemiology of anemia in human immunodeficiency virus (HIV)-infected persons: results from the multistate adult and adolescent spectrum of HIV disease surveillance project,” Blood, vol. 91, no. 1, pp. 301–308, 1998.
- R. D. Moore and D. Forney, “Anemia in HIV-infected patients receiving highly active antiretroviral therapy,” Journal of Acquired Immune Deficiency Syndromes, vol. 29, no. 1, pp. 54–57, 2002.
- A. Mocroft, O. Kirk, S. E. Barton et al., “Anaemia is an independent predictive marker for clinical prognosis in HIV-infected patients from across Europe,” AIDS, vol. 13, no. 8, pp. 943–950, 1999.
- J. D. Lundgren, A. Mocroft, J. M. Gatell, et al., “A clinically prognostic scoring system for patients receiving highly active antiretroviral therapy: results from the EuroSIDA Study,” Journal of Infectious Diseases, vol. 185, no. 1, pp. 178–187, 2002.
- R. D. Moore, J. C. Keruly, and R. E. Chaisson, “Anemia and survival in HIV infection,” Journal of Acquired Immune Deficiency Syndromes and Human Retrovirology, vol. 19, no. 1, pp. 29–33, 1998.
- World Health Organization, Worldwide Prevalence of Anemia 1993–2005: WHO Global Database on Anemia, WHO, Geneva, Switzerland, 2008.
- R. D. Semba and G. E. Gray, “Pathogenesis of anemia during human immunodeficiency virus infection,” Journal of Investigative Medicine, vol. 49, no. 3, pp. 225–239, 2001.
- A. Johannessen, E. Naman, S. G. Gundersen, and J. N. Bruun, “Antiretroviral treatment reverses HIV-associated anemia in rural Tanzania,” BMC Infectious Diseases, vol. 11, article 190, 2011.
- J. Camacho, F. Poveda, A. F. Zamorano, M. E. Valencia, J. J. Vazquez, and F. Arnalich, “Serum erythropoietin levels in anaemic patients with advanced human immunodeficiency virus infection,” British Journal of Haematology, vol. 82, no. 3, pp. 608–614, 1992.
- G. Moyle, W. Sawyer, M. Law, J. Amin, and A. Hill, “Changes in hematologic parameters and efficacy of thymidine analogue based, highly active antiretroviral therapy: a meta-analysis of six prospective, randomized, comparative studies,” Clinical Therapeutics, vol. 26, no. 1, pp. 92–97, 2004.
- M. A. Jacobson, L. Peiperl, P. A. Volberding, D. Porteous, P. T. C. Y. Toy, and D. Feigal, “Red cell transfusion therapy for anemia in patients with AIDS and ARC: incidence, associated factors, and outcome,” Transfusion, vol. 30, no. 2, pp. 133–137, 1990.
- N. Frickhofen, J. L. Abkowitz, M. Safford et al., “Persistent B19 parvovirus infection in patients infected with human immunodeficiency virus type 1 (HIV-1): a treatable cause of anemia in AIDS,” Annals of Internal Medicine, vol. 113, no. 12, pp. 926–933, 1990.
- D. W. Northfelt, A. Mayer, L. D. Kaplan et al., “The usefulness of diagnostic bone marrow examination in patients with human immunodeficiency virus (HIV) infection,” Journal of Acquired Immune Deficiency Syndromes, vol. 4, no. 7, pp. 659–666, 1991.
- M. H. McGinniss, A. M. Macher, A. H. Rook, and H. J. Alter, “Red cell autoantibodies in patients with acquired immune deficiency syndrome,” Transfusion, vol. 26, no. 5, pp. 405–409, 1986.
- A. N. Kiragga, B. Castelnuovo, D. Nakanjako, and Y. C. Manabe, “Baseline severe anaemia should not preclude use of zidovudine in antiretroviral-eligible patients in resource-limited settings,” Journal of the International AIDS Society, vol. 13, no. 1, article 42, 2010.
- F. Ssali, W. Stöhr, P. Munderi et al., “Prevalence, incidence and predictors of severe anaemia with zidovudine-containing regimens in African adults with HIV infection within the DART trial,” Antiviral Therapy, vol. 11, no. 6, pp. 741–749, 2006.
- M. P. Fox, M. Maskew, A. P. Macphail, et al., “Cohort Profile: The Themba Lethu Clinical Cohort, Johannesburg, South Africa,” International Journal of Epidemiology, vol. 42, no. 2, pp. 430–439, 2013.
- National Department of Health, Republic of South Africa, National Antiretroviral Treatment Guidelines, Jacana, 2004.
- Table for Grading the Severity of Adult and Pediatric Adverse Events, Version 1.0, National Institutes of Health Division of AIDS, 2004.
- C. J. Hoffmann, K. L. Fielding, S. Charalambous et al., “Antiretroviral therapy using zidovudine, lamivudine, and efavirenz in South Africa: tolerability and clinical events,” AIDS, vol. 22, no. 1, pp. 67–74, 2008.
- R. D. Semba, N. Shah, R. S. Klein, K. H. Maye, P. Schuman, and D. Vlahov, “Prevalence and cumulative incidence of and risk factors for anemia in a multicenter cohort study of human immunodeficiency virus-infected and -uninfected women,” Clinical Infectious Diseases, vol. 34, no. 2, pp. 260–266, 2002.
- T. S. Wills, J. P. Nadler, C. Somboonwit et al., “Anemia prevalence and associated risk factors in a single-center ambulatory HIV clinical cohort,” AIDS Reader, vol. 14, no. 6, pp. 305–310, 2004.
- J. Zhou, A. Jaquet, E. Bissagnene et al., “Short-term risk of anaemia following initiation of combination antiretroviral treatment in HIV-infected patients in countries in sub-Saharan Africa, Asia-Pacific, and central and South America,” Journal of the International AIDS Society, vol. 15, no. 1, article 5, 2012.
- S. Takuva, G. Louwagie, K. Zuma, and V. Okello, “Durability of first line antiretroviral therapy: reasons and predictive factors for modifications in a Swaziland Cohort,” Journal of Antivirals and Antiretrovirals, vol. 4, no. 1, pp. 14–20, 2012.
- R. Subbaraman, S. K. Chaguturu, K. H. Mayer, T. P. Flanigan, and N. Kumarasamy, “Adverse effects of highly active antiretroviral therapy in developing countries,” Clinical Infectious Diseases, vol. 45, no. 8, pp. 1093–1101, 2007.
- C. Laurent, A. Bourgeois, E. Mpoudi-Ngolé et al., “Tolerability and effectiveness of first-line regimens combining nevirapine and lamivudine plus zidovudine or stavudine in Cameroon,” AIDS Research and Human Retroviruses, vol. 24, supplement 3, pp. 393–399, 2008.
- D. Coetzee, K. Hildebrand, A. Boulle et al., “Outcomes after two years of providing antiretroviral treatment in Khayelitsha, South Africa,” AIDS, vol. 18, no. 6, pp. 887–895, 2004.